What 20/20 BioLabs does

20/20 BioLabs (formerly 2020 GeneSystems) is a Maryland-based diagnostic laboratory company that develops and commercializes AI-powered blood tests for early cancer detection and chronic disease risk assessment. Founded in 2000 and headquartered in Gaithersburg, MD, the company operates a CAP-accredited, CLIA-licensed laboratory at 15810 Gaither Road. Its core products are OneTest for Cancer — a multi-cancer early detection (MCED) blood test using a proprietary protein tumor marker (PTM) approach priced under $200 with at-home upper-arm capillary blood collection — and OneTest for Longevity, launched in February 2026, which uses IBM watsonx.ai (including Granite 4.0 foundation models) to analyze inflammatory biomarkers, dietary data, and peer-reviewed research for chronic disease risk prediction (diabetes, dementia, cardiovascular disease). The company holds exclusive worldwide licenses for a PSA velocity algorithm (University of South Carolina) and a U.S. CKD prediction algorithm (ROKIT Healthcare) that extend its diagnostic surface.

The company monetizes through three primary channels: (1) direct-to-consumer sales via OneTest brand websites with at-home collection kits, (2) B2B distribution through functional medicine provider networks, most notably Evexia Diagnostics' 40,000+ U.S. practitioners, and (3) state government health department contracts for occupational cancer screening programs (Vermont firefighters ~$500K, Maryland Health Department $520K). Future revenue streams include SaaS licensing of the PSA velocity algorithm to clinical laboratories globally and royalties from ROKIT Healthcare for Korea and East Asian markets. Following an all-stock merger with Longevity Health Holdings (Nasdaq: XAGE) completed in Q3 2025 at a $50M pre-money valuation, 20/20 BioLabs began trading on the Nasdaq Capital Market under ticker AIDX via direct listing on February 19, 2026. The company employs 11-50 people and is led by founder/CEO Jonathan Cohen.

Name

20/20 BioLabs

Legal name

20/20 Biolabs, Inc.

Website

https://2020biolabs.com

Company type

Public

Founded year

2000

Operating status

Operating

Headcount range

11–50 employees

Short description

20/20 BioLabs develops and commercializes AI-powered blood tests — including OneTest for Cancer (MCED) and OneTest for Longevity — for early cancer detection and chronic disease risk assessment, processing them at its CAP/CLIA laboratory in Gaithersburg, MD for consumers, functional medicine providers, and state government health departments.

Ownership category

akta.pro rank

Product category

Clinical Laboratory Diagnostics (Multi-Cancer Early Detection & Longevity)

NAICS

Medical and Diagnostic Laboratories (62151), Medical Laboratories (621511)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays (HLAAALAN)

akta.pro secondary industries

Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Clinical Chemistry & Immunoassay Laboratories (HLAFAMAB)

Keywords

• Multi-cancer early detection
• Laboratory diagnostic testing
• Longevity blood testing
• Protein tumor marker assay
• At-home blood collection kits

Headquarters

HQ city

Gaithersburg

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Laboratory Diagnostic Testing Services: Revenue generated from processing and analyzing OneTest blood tests (OneTest for Cancer and OneTest for Longevity) in the company's CAP-accredited, CLIA-licensed laboratory in Gaithersburg, Maryland. Tests are sold directly to consumers and through B2B channel partners.
2. Government/State Health Department Contracts: Revenue from government contracts such as the $500,000 Vermont firefighter cancer screening program and the $520,000 Maryland Health Department award for MCED screening. Company expects Medicare reimbursement pathway by 2028.
3. Software-as-a-Service Licensing: Plans to offer the PSA velocity algorithm to other clinical laboratories worldwide through SaaS licenses. Additional royalty revenue potential from ROKIT Healthcare for Korea and East Asian markets.
4. Public Health Testing Services: Contingency planning for Ebola and Hantavirus testing if called upon by public health agencies. Previously processed 400,000+ COVID-19 samples during 2021-2022.

Pricing tiers

Go-to-market motion4 records

Distribution channels5 records

Marketing channels5 records

Core offering

20/20 BioLabs develops, validates, and commercializes AI-powered, laboratory-developed blood tests under the OneTest brand — most notably OneTest for Cancer, a protein tumor marker-based multi-cancer early detection (MCED) assay for lung, pancreatic, ovarian, and liver cancers priced under $200 with at-home upper-arm capillary collection, and OneTest for Longevity, an IBM watsonx.ai-powered test that combines inflammatory biomarkers with dietary and lifestyle data to predict chronic disease risk. All tests are processed in the company's CAP-accredited, CLIA-licensed laboratory in Gaithersburg, Maryland, and distributed through direct-to-consumer websites, B2B functional-medicine channels, state government contracts, retail pilots, and (planned) clinical-laboratory SaaS licensing.

Product overview

20/20 BioLabs offers a portfolio of AI-powered laboratory-developed blood tests under the OneTest brand. The core offering consists of OneTest for Cancer, a multi-cancer early detection test using proprietary protein tumor marker technology priced under $200 with at-home collection capability, and OneTest for Longevity, an AI-powered longevity test using IBM watsonx.ai to analyze inflammatory biomarkers and lifestyle data for chronic disease risk assessment. The company previously provided COVID-19 testing services and is exploring Ebola and Hantavirus testing contingencies. All tests are processed in the company's CAP-accredited, CLIA-licensed laboratory in Gaithersburg, Maryland.

Differentiator

Problem solved

Functional benefit

Brands

• OneTest for Cancer: AI-powered multi-cancer early detection blood test using protein tumor marker approach. Detects multiple cancers including lung, pancreatic, ovarian, and liver at earlier stages. Available under $200 with at-home collection capability.
• OneTest for Longevity

Products and services

• OneTest for Cancer Multi-cancer early detection (MCED) blood test using a proprietary protein tumor marker (PTM) approach that detects multiple cancers including lung, pancreatic, ovarian, and liver at earlier, more treatable stages than competing DNA-based MCEDs. Priced under $200 with painless at-home upper-arm capillary blood collection and AI/ML-driven results enhanced by machine learning algorithms trained on tens of thousands of pre-diagnosis samples. Processed in a CAP-accredited, CLIA-licensed laboratory; supported by NCI blinded studies and MD Anderson Cancer Center research.
• OneTest for Longevity AI-powered blood test launched February 2026 that measures biomarkers of inflammation associated with chronic diseases including heart attacks, cancers, dementia, diabetes, and mental health. Uses IBM watsonx.ai technology (including Granite 4.0 foundation models) to analyze inflammatory biomarkers, dietary habits, and peer-reviewed scientific research, delivering personalized, evidence-based dietary and lifestyle recommendations to lower chronic inflammation and improve healthy aging.

Quantifiable outcome

• Up to 50% detection rate for early-stage pancreatic and ovarian cancers using protein biomarker approach in NCI blinded studies
• +4 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability4 records

Feature5 records

Partnerships

Six partnerships are on record, tiered supporting and core.

• National Diagnostic ServicessupportingStrategic or Co-development Partner · 27 May 2026Partnership with National Diagnostic Services for the Vermont firefighter cancer screening initiative, providing ultrasound services and medical oversight alongside 20/20 BioLabs' OneTest blood test.
• University of South CarolinacoreStrategic or Co-development Partner · 12 May 2026Exclusive worldwide licensing agreement with the University of South Carolina to commercialize Dr. James Hébert's patented PSA velocity algorithm that analyzes changes in PSA levels over time to detect aggressive prostate cancers before standard threshold crossings. 20/20 BioLabs plans to extend similar velocity algorithms for CA 125 (ovarian) and CA 19-9 (pancreatic) tumor markers in collaboration with Dr. Hébert.
• Evexia DiagnosticssupportingChannel Partner/ Reseller/ Distributor · 7 April 2026Evexia Diagnostics now offers 20/20 BioLabs' OneTest for Cancer to its network of 40,000+ U.S. practitioners in the functional medicine community, integrating the multi-cancer early detection test into proactive health insights and preventive care offerings.
• ROKIT HealthcarecoreStrategic or Co-development Partner · 26 March 2026Exclusive U.S. technology license and access agreement with ROKIT Healthcare to integrate ROKIT's proprietary CKD prediction algorithm into the 20/20 Longevity Platform. ROKIT reimburses one-third of sales and marketing expenses in exchange for running royalty on combined product net sales. ROKIT holds potential exclusive commercialization rights for Korea and East Asian markets with an 18% royalty rate.
• IBMcoreTechnology or Integration · 25 February 2026IBM watsonx.ai technology (including Granite 4.0 foundation models) powers the OneTest for Longevity AI platform to analyze inflammatory biomarkers, dietary habits, and peer-reviewed scientific research for chronic disease risk assessment.
• DAISourcesupportingTechnology or Integration · 25 February 2026Technology firm that helped deploy IBM's AI technology (watsonx.ai and Granite 4.0 foundation models) for processing biomarker and nutritional data in the OneTest for Longevity platform.

Scale indicators13 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• GRAIL: Developer of the Galleri multi-cancer early detection (MCED) blood test, the most direct ctDNA-based competitor to 20/20's OneTest for Cancer. Both target asymptomatic, multi-cancer screening from a single blood draw and compete on sensitivity, specificity, and price.
• Guardant Health: Liquid biopsy company with commercial oncology products (Guardant360, Reveal) and an MCED program (Shield). Direct competitor in blood-based cancer screening and recurrence monitoring, with broader payer coverage than 20/20.
• Freenome: Emerging liquid biopsy company developing a blood-based MCED test using a multiomics platform (cell-free DNA, methylation, proteins). Closely comparable in technology approach (protein + AI) and target indication (early-stage cancer detection).
• Exact Sciences: Commercial-stage cancer diagnostics leader (Cologuard, Oncotype DX) that has expanded into MCED via the Thrive Earlier Detection acquisition. Competes in the same blood-based, multi-cancer screening category with substantially greater scale and clinical evidence.
• Natera: Commercial-stage cell-free DNA testing company (Signatera MRD, Empower hereditary cancer screening) competing in the same blood-based cancer detection and monitoring category with established clinical evidence and reimbursement.
• Function Health: Direct-to-consumer longevity and preventive diagnostics platform offering 100+ blood biomarker tests with AI-driven insights. Closely comparable to OneTest for Longevity in business model, consumer audience, and chronic-disease risk positioning.

Broad incumbents

• Quest Diagnostics: One of the two largest U.S. clinical reference laboratories with broad diagnostic test menus. Provides scale benchmarks, lab-services incumbency, and potential partnership/M&A optionality for 20/20's biomarker and LDT franchise.
• Laboratory Corporation of America (Labcorp): Second major U.S. clinical reference laboratory and oncology diagnostics player (former BioReference, which is also connected to 20/20's board). Comparable as a broad incumbent that could partner, distribute, or compete with 20/20's MCED and longevity tests.

Emerging players

• Burning Rock Biotech: China-based cancer genomics and liquid biopsy company with overlapping MCED/MRD programs and an early-stage commercialization model, comparable to 20/20 in development stage and target markets.
• Personalis: Cancer genomics company focused on tumor profiling and MRD (NeXT Personal), with AI-driven analytics similar to 20/20's PTM approach. Comparable in technology orientation though earlier in commercial scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 20/20 BioLabs